Recent news that the FDA has granted the fastest possible review for Biogen’s Alzheimer disease treatment aducanumab may be indicative of the agency’s increasing confidence in the drug.
James W. Kupiec, MD
Advertisement
Articles by James W. Kupiec, MD
Advertisement
Latest Updated Articles
Aducanumab's Unlikely Road to the FDA: Is Approval Imminent?August 14th 2020
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Survey Data Suggest Deutetrabenazine May Improve Quality of Life Measures in Huntington Disease Chorea
2
Earlier Pimavanserin Initiation May Alter Psychosis Symptom Trajectory in Parkinson's Disease, Exploratory Analysis Suggests
3
Discontinuing Disease-Modifying Therapy in Older Patients With MS: John Corboy, MD
4
Anti-PACAP Antibody Bocunebart Meets Primary Endpoint in Phase 2b Migraine Prevention Trial
5